- Home
- NBXG vs IMTX Comparison
NBXG vs IMTX Comparison
Compare NBXG & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBXG | IMTX |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NBXG | IMTX |
|---|---|---|
| Price | $15.40 | $9.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 174.3K | ★ 541.4K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.32 | $5.05 |
| 52 Week High | $17.43 | $12.41 |
Technical Indicators
Market Signals| Indicator | NBXG | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.08 | 51.04 |
| Support Level | $14.83 | $9.37 |
| Resistance Level | $15.93 | $10.41 |
| Average True Range (ATR) | 0.32 | 0.43 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 40.13 | 62.66 |
Price Performance
Historical ComparisonAbout NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in NextGen Companies.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.